Logotype for Bubs Australia Limited

Bubs Australia (BUB) H1 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Bubs Australia Limited

H1 2026 earnings summary

27 Feb, 2026

Executive summary

  • Revenue increased 14% year-over-year to $55.5 million, driven by a 48% surge in US revenue and expanded store presence, while Australia and China revenues declined due to supply constraints.

  • Underlying EBITDA improved to $4.4 million from a loss of $0.7 million, with reported EBITDA at $3.0 million, reflecting operational improvements despite higher air freight and tariff costs.

  • Gross margin held at 48%, reflecting premium brand positioning and improved inventory management, though slightly down from over 50% in the prior period.

  • Discontinued non-core food portfolio to focus on core infant formula business and optimize performance in Australia.

  • Strategic initiatives aligned with 2030 strategy pillars, including transformation office launch and upweighted digital marketing.

Financial highlights

  • US revenue surged 48% year-over-year to $34.2 million, now the largest and most profitable region, while China revenue declined 27% to $7.5 million and Australia fell 9% to $9.5 million.

  • Gross margin at 48% for the half year, outperforming guidance of 40%-45% despite air freight and tariff impacts.

  • Operating expenses to revenue ratio improved to 44% from 52% year-over-year, with total operating expenses decreasing.

  • Cash and cash equivalents at period end were $9.9 million, down from $17.4 million at June 2025, due to inventory investment.

  • Net working capital rose to $33.4 million, supporting inventory expansion.

Outlook and guidance

  • FY26 revenue guidance upgraded to $120 million–$125 million, representing 22%-27% growth over the prior period.

  • Gross profit margin forecasted in the 40%-45% range for FY26.

  • Underlying EBITDA guidance raised to $9 million–$11 million for FY26.

  • Progressing toward permanent FDA approval for US market access, with current sales allowed under Enforcement Discretion.

  • Directors assume FDA approval and bank facility extension in their going concern assessment, but acknowledge material uncertainty if these are not achieved.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more